Ross L. Levine, MD

Dr. Levine is a physician-scientist and Member of the Human Oncology and Pathogenics Program; and Attending Physician on the Leukemia Service, Department of Medicine; the Laurence Joseph Dineen Chair in Leukemia Research; and the director of the Memorial Sloan Kettering Center for Hematologic Malignancies. He received his AB from Harvard College and MD from Johns Hopkins University. Dr. Levine served as a resident in Internal Medicine at Massachusetts General Hospital and subsequently as a Hematology-Oncology Fellow at Dana-Farber Cancer Institute. In 2003, Dr. Levine joined Gary Gilliland’s laboratory for his postdoctoral fellowship and performed kinome sequencing at the Broad Institute to identify JAK2V617F and MPL mutation in MPN patients. In 2007, he was recruited to MSK’s Human Oncology and Pathogenesis Program.

Dr. Levine’s laboratory seeks to improve our understanding of the genetic basis of myeloid malignancies, with a specific focus on the role of oncogenic disease alleles in the pathogenesis of myeloproliferative neoplasms (MPS) and acute myeloid leukemia (AML). His current efforts focus on the role of mutations in epigenetic modifiers in MPN and AML pathogenesis and therapeutic response; investigation of the role of different signaling pathways in hematopoietic transformation; and characterization of targeted therapies in MPN/AML patients using in vitro and in vivo assays, and elucidation of the mechanisms of resistance to these therapies.

Dr. Levine has published nearly 200 scientific papers, sits on the Scientific Advisory Board of several foundations and therapeutics companies, and serves as one of the lead investigators on the Leukemia & Lymphoma Society’s Beat AML Master Trial.